AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended June 30, 2026																		Full-Year Ended December 31, 2026
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense			$	—					$	3.74					$	3.78					$	744					$	14.08					$	14.28
Q2 2026 acquired IPR&D and milestones expense			291						(0.17)						(0.17)						291						(0.17)						(0.17)
Guidance including Q2 2026 acquired IPR&D and milestones expensea			$	291					$	3.57					$	3.61					$	1,035					$	13.91					$	14.11

a    The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.

    1